An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Dacarbazine versus Dacarbazine Alone as First Line Therapy in Patients with Stage IV Melanoma

Update Il y a 4 ans
Reference: EUCTR2009-016049-24

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

• Phase Ib: to define the safety, tolerability and maximum tolerated dose (MTD) of E7080 administered in combination with dacarbazine in patients with Stage IV melanoma. • Phase II: to evaluate the safety and tolerability of E7080 administered in combination with dacarbazine, compared with dacarbazine alone, in patients with Stage IV melanoma.


Inclusion criteria

  • Stage IV Melanoma